Pinnacle Medicines raised $89 million in a Series B financing to support development of its oral peptide programs, bringing total funding to $134 million. The round was co-led by LAV and Foresite Capital, with additional participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, Orbimed, and other investors. The company’s financing focus is on taking its oral peptide pipeline through preclinical and clinical milestones, leveraging the growing market interest in oral delivery systems built for peptide therapeutics. Pinnacle also aligns with the broader competitive push to convert traditionally injectable peptide drugs into oral formats. For investors and partners, the oversubscription signals continued appetite for platform-led drug development in modalities where oral bioavailability and manufacturability remain key barriers.